Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis
Information source: University of Padova
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Persistent Knee Joint Synovitis
Intervention: etanercept (Drug); placebo (Drug)
Phase: Phase 2
Sponsored by: University of Padova
Official(s) and/or principal investigator(s):
Ugo Fiocco, MD, PhD, Principal Investigator, Affiliation: University of Padova
To assess the therapeutic efficacy, of the clinical response of intraarticular (IA)
etanercept (E) 12. 5 mg or placebo (P: NaCl) injections into single knee arthritic joint of
patients with refractory knee joint synovitis (KJS), administered once every two week, for
eight weeks, with cross over after 2 weeks, in two groups of randomly assigned patients, for
whom traditional systemic disease-modifying antirheumatic drugs (DMARDs) is insufficient or
inappropriate. The primary outcome measure is the Thompson articular index of KJS disease
Official title: Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Thompson articular index
Secondary outcome: Knee Joint Articular Index
The study is a single centre, placebo-controlled, single-blind, cross-over trial, with
randomization of treatment sequence and open-label extension to be conducted in rheumatoid
arthritis, psoriatic arthritis and spondyloarthropathies patients with resistant knee joint
Patients are eligible if they suffered from persistent active KJS (characterized by pain,
tenderness, and effusion), which had proved resistant to surgical treatment or to repeated
IA corticosteroid therapy, or unresponsive to a minimum of 6 months second-line drug
therapy with DMARD-, and/or anti-TNFα biologic agent monotherapy and systemic oral
corticosteroid treatment, or to a combination therapy (drug failure is defined as
discontinuation because of intolerable adverse effects or lack of clinical efficacy).
Concomitant Treatments: stable, appropriate doses of DMARDs (methotrexate, sulfasalazine,
hydroxychloroquine, cyclosporine), DMARD combinations or low dose oral corticosteroids (≤10
mg prednisone) with or without non-steroid anti-inflammatory agents will be continued
throughout the study.
Patients will be permitted stable doses (no greater than the maximum dose recommended by the
manufacturer) of non-steroidal anti-inflammatory drugs (NSAIDs) but will be permitted to use
only one NSAID at any given time. No analgesic could be taken before undergoing assessment
on the day clinical evaluations will be performed.
Treatment: Each dose of study drug will be administered as one intraarticular (IA)injection
carried out in each single knee joint that will be randomly assigned to blind treatment
with 0. 5 ml of etanercept (E) (12. 5mg) or placebo (P) (NaCl). The IA injection will be
administered once every two weeks for an eight week period. After 2 weeks time the patients
will be crossed-over and each arthritic knee joint will receive E (12. 5 mg) for four times
or P for three times, respectively, administered every two weeks for an eight week period.
All the IA injections will be administered after synovial fluid aspiration by the same
operator. The study, patients with KJS flare up after IA injection will be asked to enter
the open-label IA extension treatment with IA-E injection once every two weeks, for eight
Safety assessment: routine chemistry, haematology and urinalysis assessments will be
performed at the screening, baseline and final examinations. Tuberculosis screening will be
performed at the onset of the study. Patients will be evaluated clinically for adverse
events at each examination. Local tolerance at the injection site(s) will be evaluated at
all the controls.
Assessment of the patients' response: will be performed at baseline (T0) and at 2 (T2), 4
(T4), 6 (T6), and 8 (T8) weeks, and at the end of the 10 week single-blind, cross-over study
or at the end of the open-label IA extension-study (up to 14 weeks) (Tend).
The primary efficacy endpoint is the Thompson articular index (THOMP) sum of scores for
each knee joint, of pain on movement (0-3), soft tissue swelling (0-3) and warmth (0-3);
(range 0-9). Secondary endpoints are: the Knee joint articular index (KJAI): the sum of the
tenderness scores (0-3), joint swelling (0-3), the ballottement of patella or the "bulge
sign" (0-2), and range of knee joint flexion (0-3) and extension (0-3) (KJAI, range 0-14).
Standard joint evaluation comprise: the 66/68 swollen joint number (SJN) and tender joint
number (TJN) (0-1); a modified Ritchie articular index (RAI), by assessment of 30 joints for
tenderness (0-3) (range: 0-90), (including hand and foot distal interphalangeal joints (DIP)
of each side as a group; the pain visual analogue scale (VAS) (0-100mm), the health
assessment questionnaire (HAQ)- disability index (0-3) and the SF36 (range 0-24) at the
above time points.
The serum CRP, the ESR, and the maximal synovial thickness (measured by grey-scale
ultrasonography and contrast-enhanced magnetic resonance imaging) will be assessed at
baseline and at the end of the treatment.
Minimum age: 18 Years.
Maximum age: N/A.
- Male or female patients 18 years of age or older and of legal age of consent.
- A negative serum pregnancy test at screening and use of a medically acceptable form
of contraception starting at screening and continuing throughout the study, is
required for all females of childbearing potential (defined as an oral, injectable,
or implantable contraceptive, intrauterine device, or barrier method combined with a
- Meet the 1987 American Rheumatism Association (ARA) revised criteria for Rheumatoid
Arthritis(RA) and generally accepted criteria for psoriatic (PsA) or
- Meet the following criteria at both the screening visit and the baseline visit:
- Refractory KJS defined by the presence of: Persistence of active synovitis of
the knee (characterized by pain, tenderness and effusion), which had proved
resistant to at least 6 months second-line DMARD therapy
- Failure drug therapy with at least one DMARD and/or anti-TNFα biologic agent,
and/or systemic or IA corticosteroid treatment. (Drug failure is defined as a
drug discontinuation because of lack of clinical efficacy or intolerable adverse
- Normal chest X-ray as clinically indicated.
- Provide written informed consent.
- In the opinion of the investigator, the patient will be able to comply with the
requirements of the protocol.
- Uncooperative patients with a history of poor compliance.
- Known hypersensitivity to etanercept or any of its components.
- Known significant concurrent medical disease including:
- cancer or history of cancer (other than resected basal cell carcinoma of the
- congestive heart failure
- myocardial infarction within 12 months of the screening visit
- uncontrolled angina pectoris
- active infection
- sepsis or at risk of sepsis
- severe pulmonary disease
- known HIV infection
- liver function abnormality (SGOT/AST, SGPT/ALT: greater than two times the upper
limit of normal); liver cirrhosis or fibrosis
- renal disease (creatinine level >175umol/L)
- leukopenia (white blood cells <3. 5 x 109/L)
- thrombocytopenia (<1. 25 x 1011/L)
- haemoglobin = 8. 5 g/dL
- Females who are pregnant, breast feeding or at risk of pregnancy and not using a
medically acceptable form of contraception.
- Any condition judged by the investigator that would cause the study to be detrimental
to the patient.
- Use of any investigational drug within four weeks of the screening visit.
- In the opinion of the investigator, the patient shows persistent signs of
- Receipt of any live attenuated vaccine within eight weeks before the screening visit.
Locations and Contacts
Centro Multidisciplinare di Day Surgery, Azienda Ospedaliera di Padova, Ospedale Busonera, via Gattamelata 64, Padova 35128, Italy
Starting date: April 2005
Last updated: May 15, 2008